Protective effects of fucoidan against kidney diseases: Pharmacological insights and future perspectives.

Chronic kidney disease (CKD) is a major public health concern that costs millions of lives worldwide. Natural products are consistently being explored for the development of novel therapeutics in the management of CKD. Fucoidan is a sulfated polysaccharide predominantly extracted from brown seaweed, which has multiple pharmacological benefits against various kidney problems, including chronic renal failure and diabetic nephropathy. This review aimed at exploring literature to update the renoprotective effects of fucoidan, to get an understanding of pharmacological mechanisms, and to highlight the recent progress of fucoidan-based therapeutic development. Evidence shows that fucoidan is effective against inflammation, oxidative stress, and fibrosis in kidney. Fucoidan targets multiple signaling systems, including Nrf2/HO-1, NF-κB, ERK and p38 MAPK, TGF-ß1, SIRT1, and GLP-1R signaling that are known to be associated with CKD pathobiology. Despite these pharmacological prospects, the application of fucoidan is limited by its larger molecular size. Notably, low molecular weight fucoidan has shown therapeutic promise in some recent studies. However, future research is warranted to translate the outcome of preclinical studies into clinical use in kidney patients.

Repositioning Vitamin C as a Promising Option to Alleviate Complications associated with COVID-19.

Vitamin C, also known as L-ascorbic acid, is an essential vitamin with pleiotropic functions, ranging from antioxidant to anti-microbial functions. Evidence suggests that vitamin C acts against inflammation, oxidative stress, autophagy chaos, and immune dysfunction. The ability to activate and enhance the immune system makes this versatile vitamin a prospective therapeutic agent amid the current situation of coronavirus disease 2019 (COVID-19). Being highly effective against the influenza virus, causing the common cold, vitamin C may also function against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its associated complications. Severe infections need higher doses of the vitamin to compensate for the augmented inflammatory response and metabolic demand that commonly occur during COVID-19. Compelling evidence also suggests that a high dose of vitamin C (1.5 g/kg body weight) in inflammatory conditions can result in effective clinical outcomes and thus can be employed to combat COVID-19. However, further studies are crucial to delineate the mechanism underlying the action of vitamin C against COVID-19. The current review aims to reposition vitamin C as an alternative approach for alleviating COVID-19-associated complications.